Richard G Wunderink1, Wesley H Self2, Evan J Anderson3,4, Robert Balk5, Sherene Fakhran6, Daniel Mark Courtney1, Chao Qi1, Derek J Williams2, Yuwei Zhu2, Cynthia G Whitney7, Matthew R Moore7, Anna Bramley7, Seema Jain7, Kathryn M Edwards2, Carlos G Grijalva2,8. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 4. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 5. Rush University Medical Center, Chicago, Illinois. 6. John H. Stroger, Jr, Hospital of Cook County, Chicago, Illinois. 7. Centers for Disease Control and Prevention, Atlanta, Georgia. 8. Health Services Research & Development Center, Geriatric Research Education Clinical Center, Veterans Health Administration-Tennessee Valley Healthcare System, Nashville.
Abstract
Background: Streptococcus pneumoniae is considered the leading bacterial cause of pneumonia in adults. Yet, it was not commonly detected by traditional culture-based and conventional urinary testing in a recent multicenter etiology study of adults hospitalized with community-acquired pneumonia (CAP). We used novel serotype-specific urinary antigen detection (SSUAD) assays to determine whether pneumococcal cases were missed by traditional testing. Methods: We studied adult patients hospitalized with CAP at 5 hospitals in Chicago and Nashville (2010-2012) and enrolled in the Etiology of Pneumonia in the Community (EPIC) study. Traditional diagnostic testing included blood and sputum cultures and conventional urine antigen detection (ie, BinaxNOW). We applied SSUAD assays that target serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) to stored residual urine specimens. Results: Among 1736 patients with SSUAD and ≥1 traditional pneumococcal test performed, we identified 169 (9.7%) cases of pneumococcal CAP. Traditional tests identified 93 (5.4%) and SSUAD identified 76 (4.4%) additional cases. Among 14 PCV13-serotype cases identified by culture, SSUAD correctly identified the same serotype in all of them. Cases identified by SSUAD vs traditional tests were similar in most demographic and clinical characteristics, although disease severity and procalcitonin concentration were highest among those with positive blood cultures. The proportion of pneumonia cases caused by serotypes exclusively covered by PCV13 was not significantly different between the first and second July-June study periods (6.4% vs 4.0%). Conclusions: Although restricted to the detection of only 13 serotypes, SSUAD testing substantially increased the detection of pneumococcal pneumonia among adults hospitalized with CAP.
Background: Streptococcus pneumoniae is considered the leading bacterial cause of pneumonia in adults. Yet, it was not commonly detected by traditional culture-based and conventional urinary testing in a recent multicenter etiology study of adults hospitalized with community-acquired pneumonia (CAP). We used novel serotype-specific urinary antigen detection (SSUAD) assays to determine whether pneumococcal cases were missed by traditional testing. Methods: We studied adult patients hospitalized with CAP at 5 hospitals in Chicago and Nashville (2010-2012) and enrolled in the Etiology of Pneumonia in the Community (EPIC) study. Traditional diagnostic testing included blood and sputum cultures and conventional urine antigen detection (ie, BinaxNOW). We applied SSUAD assays that target serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) to stored residual urine specimens. Results: Among 1736 patients with SSUAD and ≥1 traditional pneumococcal test performed, we identified 169 (9.7%) cases of pneumococcal CAP. Traditional tests identified 93 (5.4%) and SSUAD identified 76 (4.4%) additional cases. Among 14 PCV13-serotype cases identified by culture, SSUAD correctly identified the same serotype in all of them. Cases identified by SSUAD vs traditional tests were similar in most demographic and clinical characteristics, although disease severity and procalcitonin concentration were highest among those with positive blood cultures. The proportion of pneumonia cases caused by serotypes exclusively covered by PCV13 was not significantly different between the first and second July-June study periods (6.4% vs 4.0%). Conclusions: Although restricted to the detection of only 13 serotypes, SSUAD testing substantially increased the detection of pneumococcal pneumonia among adults hospitalized with CAP.
Authors: Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller Journal: Lancet Date: 2004-02-21 Impact factor: 79.321
Authors: Aaron M Harris; Anna M Bramley; Seema Jain; Sandra R Arnold; Krow Ampofo; Wesley H Self; Derek J Williams; Evan J Anderson; Carlos G Grijalva; Jonathan A McCullers; Andrew T Pavia; Richard G Wunderink; Kathryn M Edwards; Jonas M Winchell; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2017-02-10 Impact factor: 3.835
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller Journal: BMC Health Serv Res Date: 2007-07-05 Impact factor: 2.655
Authors: Naomi J Gadsby; Clark D Russell; Martin P McHugh; Harriet Mark; Andrew Conway Morris; Ian F Laurenson; Adam T Hill; Kate E Templeton Journal: Clin Infect Dis Date: 2016-01-07 Impact factor: 9.079
Authors: John M McLaughlin; Qin Jiang; Raul E Isturiz; Heather L Sings; David L Swerdlow; Bradford D Gessner; Ruth M Carrico; Paula Peyrani; Timothy L Wiemken; William A Mattingly; Julio A Ramirez; Luis Jodar Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Geert H Groeneveld; Tanny J van der Reyden; Simone A Joosten; Hester J Bootsma; Christa M Cobbaert; Jutte J C de Vries; Ed J Kuijper; Jaap T van Dissel Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: N Takeuchi; S Naito; M Ohkusu; K Abe; K Shizuno; Y Takahashi; Y Omata; T Nakazawa; K Takeshita; H Hishiki; T Hoshino; Y Sato; N Ishiwada Journal: Epidemiol Infect Date: 2020-04-17 Impact factor: 2.451
Authors: Jason LeBlanc; May ElSherif; Lingyun Ye; Donna MacKinnon-Cameron; Ardith Ambrose; Todd F Hatchette; Amanda Ls Lang; Hayley D Gillis; Irene Martin; Walter H Demczuk; Craig LaFerriere; Melissa K Andrew; Guy Boivin; William Bowie; Karen Green; Jennie Johnstone; Mark Loeb; Anne McCarthy; Allison McGeer; Makeda Semret; Sylvie Trottier; Louis Valiquette; Duncan Webster; Shelly A McNeil Journal: BMJ Open Respir Res Date: 2020-03